Highlights of Vitreoretina

Register      Login

VOLUME 6 , ISSUE 3 ( September, 2013 ) > List of Articles


Toxoplasmosis Ocular

Cheryl A. Arcinue, C. Stephen Foster

Citation Information : Arcinue CA, Foster CS. Toxoplasmosis Ocular. 2013; 6 (3):13-18.

DOI: 10.5005/hov-10102-06304

Published Online: 26-12-2020

Copyright Statement:  Copyright © 2013; Jaypee Brothers Medical Publishers (P) Ltd.


PDF Share
  1. Butler NJ, Furtado JM, Winthrop KL, Smith JR. Ocular toxoplasmosis II: clinical features, pathology and management. Clinical & experimental ophthalmology 2013;41:95-108.
  2. Bonfioli AA, Orefice F. Toxoplasmosis. Seminars in ophthalmology 2005;20:129-41.
  3. Englander M, Young LH. Ocular toxoplasmosis: advances in detection and treatment. International ophthalmology clinics 2011;51:13-23.
  4. Stanford MR, Gilbert RE. Treating ocular toxoplasmosis: current evidence. Memorias do Instituto Oswaldo Cruz 2009;104:312-5.
  5. Stanford MR, See SE, Jones LV, Gilbert RE. Antibiotics for toxoplasmic retinochoroiditis: an evidence-based systematic review. Ophthalmology 2003;110:926-31; quiz 31-2.
  6. Balaskas K, Vaudaux J, Boillat-Blanco N, Guex-Crosier Y. Azithromycin versus Sulfadiazine and Pyrimethamine for non-vision-threatening toxoplasmic retinochoroiditis: a pilot study. Medical science monitor : international medical journal of experimental and clinical research 2012;18:CR296-302.
  7. Kim SJ, Scott IU, Brown GC, et al. Interventions for toxoplasma retinochoroiditis: a report by the american academy of ophthalmology. Ophthalmology 2013;120:371- 8.
  8. Colin J, Harie JC. [Presumed toxoplasmic chorioretinitis: comparative study of treatment with pyrimethamine and sulfadiazine or clindamycin]. Journal francais d'ophtalmologie 1989;12:161-5.
  9. Soheilian M, Sadoughi MM, Ghajarnia M, et al. Prospective randomized trial of trimethoprim/sulfamethoxazole versus pyrimethamine and sulfadiazine in the treatment of ocular toxoplasmosis. Ophthalmology 2005;112:1876-82.
  10. Bosch-Driessen LH, Verbraak FD, Suttorp-Schulten MS, et al. A prospective, randomized trial of pyrimethamine and azithromycin vs pyrimethamine and sulfadiazine for the treatment of ocular toxoplasmosis. American journal of ophthalmology 2002;134:34-40.
  11. Soheilian M, Ramezani A, Azimzadeh A, et al. Randomized trial of intravitreal clindamycin and dexamethasone versus pyrimethamine, sulfadiazine, and prednisolone in treatment of ocular toxoplasmosis. Ophthalmology 2011;118:134- 41.
  12. Sobrin L, Kump LI, Foster CS. Intravitreal clindamycin for toxoplasmic retinochoroiditis. Retina 2007;27:952-7.
  13. Lasave AF, Diaz-Llopis M, Muccioli C, Belfort R, Jr., Arevalo JF. Intravitreal clindamycin and dexamethasone for zone 1 toxoplasmic retinochoroiditis at twenty-four months. Ophthalmology 2010;117:1831-8.
  14. Kump LI, Androudi SN, Foster CS. Ocular toxoplasmosis in pregnancy. Clinical & experimental ophthalmology 2005;33:455-60.
  15. Holland GN, Crespi CM, ten Dam-van Loon N, et al. Analysis of recurrence patterns associated with toxoplasmic retinochoroiditis. American journal of ophthalmology 2008;145:1007-13.
  16. Silveira C, Belfort R, Jr., Muccioli C, et al. The effect of long-term intermittent trimethoprim/sulfamethoxazole treatment on recurrences of toxoplasmic retinochoroiditis. American journal of ophthalmology 2002;134:41-6.
  17. O'Connor GR, Frenkel JK. Editorial: Dangers of steroid treatment in toxoplasmosis. Periocular injections and systemic therapy. Archives of ophthalmology 1976;94:213.
  18. Martinez CE, Zhang D, Conway MD, Peyman GA. Successful management of ocular toxoplasmosis during pregnancy using combined intraocular clindamycin and dexamethasone with systemic sulfadiazine. International ophthalmology 1998;22:85-8.
  19. Adan A, Mateo C, Navarro R, Bitrian E, Casaroli-Marano RP. Intravitreal bevacizumab (avastin) injection as primary treatment of inflammatory choroidal neovascularization. Retina 2007;27:1180-6.
  20. Ben Yahia S, Herbort CP, Jenzeri S, et al. Intravitreal bevacizumab (Avastin) as primary and rescue treatment for choroidal neovascularization secondary to ocular toxoplasmosis. International ophthalmology 2008;28:311-6.
  21. Rouvas A, Petrou P, Douvali M, et al. Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 2011;31:871-9.
  22. Benevento JD, Jager RD, Noble AG, et al. Toxoplasmosis-associated neovascular lesions treated successfully with ranibizumab and antiparasitic therapy. Archives of ophthalmology 2008;126:1152-6.
  23. Mauget-Faysse M, Mimoun G, Ruiz-Moreno JM, et al. Verteporfin photodynamic therapy for choroidal neovascularization associated with toxoplasmic retinochoroiditis. Retina 2006;26:396-403.
  24. Rishi P, Venkataraman A, Rishi E. Combination photodynamic therapy and bevacizumab for choroidal neovascularization associated with toxoplasmosis. Indian journal of ophthalmology 2011;59:62-4.
  25. Adan A, Giralt J, Alvarez G, et al. Pars plana vitrectomy for vitreoretinal complications of ocular toxoplasmosis. European journal of ophthalmology 2009;19:1039-43.
  26. Bovey EH. Usefulness of vitrectomy in the treatment of ocular toxoplasmosis. International journal of medical sciences 2009;6:139.
  27. Sauer A, Pfaff AW, Villard O, et al. Interleukin 17A as an effective target for antiinflammatory and antiparasitic treatment of toxoplasmic uveitis. The Journal of infectious diseases 2012;206:1319-29.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.